Scoring systems for estimating the risk of anticoagulant-associated bleeding
AL Parks, MC Fang - Seminars in thrombosis and hemostasis, 2017 - thieme-connect.com
Anticoagulant medications are frequently used to prevent and treat thromboembolic disease.
However, the benefits of anticoagulants must be balanced with a careful assessment of the …
However, the benefits of anticoagulants must be balanced with a careful assessment of the …
[HTML][HTML] Real-world data and recommended dosage of non-vitamin K oral anticoagulants for Korean patients
B Joung - Korean Circulation Journal, 2017 - ncbi.nlm.nih.gov
Regulatory approvals of non-vitamin K antagonist oral anticoagulants (NOACs) have been
based on large randomized phase III trials evaluating dabigatran, rivaroxaban, apixaban, or …
based on large randomized phase III trials evaluating dabigatran, rivaroxaban, apixaban, or …
Risk for venous thromboembolism recurrence among rivaroxaban-treated patients who continued versus discontinued therapy: analyses among patients with VTE
Abstract Purpose The EINSTEIN-Extension trial showed that an extended rivaroxaban
treatment significantly reduced the risk for venous thromboembolic (VTE) recurrence. The …
treatment significantly reduced the risk for venous thromboembolic (VTE) recurrence. The …
Management of acute stroke in patients on oral anticoagulants
JC Purrucker, T Steiner - Current Opinion in Neurology, 2017 - journals.lww.com
Management of acute stroke in patients on oral anticoagulant... : Current Opinion in
Neurology Management of acute stroke in patients on oral anticoagulants : Current Opinion …
Neurology Management of acute stroke in patients on oral anticoagulants : Current Opinion …
Evaluation of the efficacy and safety of direct oral anticoagulants in Japanese patients—analysis of pharmaceuticals and medical devices agency data
Y Terayama - Journal of Stroke and Cerebrovascular Diseases, 2017 - Elsevier
Background Two forms of direct oral anticoagulant (DOAC) have recently been introduced:
direct thrombin inhibitors (DTI; eg, dabigatran) and factor Xa inhibitors (FXa; eg, rivaroxaban …
direct thrombin inhibitors (DTI; eg, dabigatran) and factor Xa inhibitors (FXa; eg, rivaroxaban …
[HTML][HTML] Приверженность к приему новых пероральных антикоагулянтов у больных с фибрилляцией предсердий-путь к решению проблемы эффективности и …
СГ Канорский - Рациональная фармакотерапия в кардиологии, 2017 - cyberleninka.ru
Фибрилляция предсердий (ФП) увеличивает риск развития инсульта, поэтому
долгосрочная антикоагулянтная терапия является стандартом лечения абсолютного …
долгосрочная антикоагулянтная терапия является стандартом лечения абсолютного …
De los ensayos clínicos a la práctica clínica. Evidencias con rivaroxaban en el tratamiento anticoagulante del paciente con fibrilación auricular no valvular
A pesar de que la información proporcionada por los ensayos clínicos es importante,
existen diferencias relevantes entre los pacientes incluidos en los ensayos clínicos y los …
existen diferencias relevantes entre los pacientes incluidos en los ensayos clínicos y los …
Bleeding-related admissions in patients with atrial fibrillation receiving antithrombotic therapy: results from the Tasmanian Atrial Fibrillation (TAF) study
E Admassie, L Chalmers, LR Bereznicki - European journal of clinical …, 2017 - Springer
Purpose Limited data are available from the Australian setting regarding bleeding in patients
with atrial fibrillation (AF) receiving antithrombotic therapy. We aimed to investigate the …
with atrial fibrillation (AF) receiving antithrombotic therapy. We aimed to investigate the …
Comparative effectiveness of rivaroxaban in the treatment of nonvalvular atrial fibrillation
Rivaroxaban is a direct oral anticoagulant (DOAC) approved for the prevention of stroke and
systemic embolism in patients with nonvalvular atrial fibrillation, a common arrhythmia. In …
systemic embolism in patients with nonvalvular atrial fibrillation, a common arrhythmia. In …
[HTML][HTML] Приверженность к лечению пероральными антикоагулянтами у пациентов с неклапанной фибрилляцией предсердий в реальной клинической …
НМ Воробьева, ЮА Карпов - Атмосфера. Новости кардиологии, 2017 - cyberleninka.ru
В статье рассмотрены результаты наблюдательных исследований по оценке
приверженности к лечению пероральными антикоагулянтами в реальной клинической …
приверженности к лечению пероральными антикоагулянтами в реальной клинической …